Inify Laboratories AB — Earnings Release 2025

Feb 25, 2026

Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics

Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics

STOCKHOLM - February 25, 2026 - Inify Laboratories, a unique laboratory service

that provides diagnostics within pathology, reports continued sales growth in

the fourth quarter of 2025. Significant progress has been made in establishing

its UK laboratory as well as a positive market response to its gastrointestinal

diagnostics services in Sweden.

Sales growth during the quarter was driven primarily by prostate cancer

diagnostics, increasing by 33% compared to the same period last year, and by 62%

for the full year.

"We continue to see strong demand for our diagnostics, which confirms the

tangible value we deliver to healthcare providers and patients," says CEO

Fredrik Palm of Inify Laboratories.

Progress in the UK and growing NHS interest

During the quarter, Inify gained access to its newly built laboratory premises

in the UK and began installing laboratory equipment. Applications for regulatory

permits to conduct routine medical activities have been submitted, and testing

and verification of the full system are planned to begin shortly.

Dialogue with the UK public healthcare system (NHS) has intensified at both

national and regional levels, including funded pilot projects. Representatives

from NHS hospitals visited Inify's laboratory in Sweden during the quarter.

"Our discussions with NHS stakeholders are progressing well. While the system is

complex, the level of engagement we see gives us confidence as we move forward,"

says Palm.

Initial UK services will focus on prostate cancer diagnostics, with

gastrointestinal diagnostics to be introduced gradually.

Positive response to gastrointestinal diagnostics

Inify's gastrointestinal diagnostics services were launched in Sweden in

September, with the first patient samples successfully diagnosed during the

quarter. Customer feedback has been consistently positive, and the company sees

strong long-term potential driven by large sample volumes and capacity

constraints within the healthcare system.

"There is a clear need for faster, high-quality diagnostics in this area, and we

are confident that our services will make sustainable and tangible improvement,"

says Palm.

Strengthened financial position

During the quarter, Inify initiated a fully guaranteed share issue of NOK 100

million, directed to existing shareholders. The capital injection supports

continued investment in the UK and provides resilience in sales processes with

longer lead times, particularly within the public sector.

"We are grateful for the strong confidence shown by our shareholders. This

financing gives us both stability and endurance as we execute our growth

strategy," says Palm.

Outlook

Inify Laboratories closes the year with sustained growth, solid financing, and

increasing customer engagement across its markets.

"We have made significant progress during the year, and I look ahead with great

confidence," concludes Palm.

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)